Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.6814
+0.0435 (6.82%)
At close: Jun 13, 2025, 4:00 PM
0.6700
-0.0114 (-1.67%)
After-hours: Jun 13, 2025, 5:18 PM EDT

Company Description

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.

Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease.

The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation.

Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee’s Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate.

The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics, Inc.
Unicycive Therapeutics logo
Country United States
Founded 2016
IPO Date Jul 13, 2021
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Shalabh Gupta

Contact Details

Address:
4300 El Camino Real, Suite 210
Los Altos, California 94022
United States
Phone 650 351 4495
Website unicycive.com

Stock Details

Ticker Symbol UNCY
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001766140
CUSIP Number 90466Y103
ISIN Number US90466Y1038
Employer ID 81-3638692
SIC Code 2834

Key Executives

Name Position
Dr. Shalabh K. Gupta M.D., MPA Founder, Chairman, Chief Executive Officer and President
Dr. Pramod Gupta Ph.D. Executive Vice President of Pharmaceutical and Business Operations
Douglas Jermasek M.B.A. Executive Vice President of Corporate Strategy
John W. Townsend CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Jun 13, 2025 424B5 Filing
Jun 10, 2025 8-K Current Report
Jun 9, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 9, 2025 8-K Current Report
May 22, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 21, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 21, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G/A Filing